Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT02258464. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy
Study identification
- NCT ID
- NCT02258464
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 99 participants
Conditions and interventions
Conditions
Interventions
- Background hormonal therapy Other
- Placebo (saline) Drug
- Radium-223 dichloride (Xofigo, BAY88-8223) Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2015
- Primary completion
- Aug 12, 2019
- Completion
- Aug 12, 2019
- Last update posted
- Aug 9, 2020
2015 – 2019
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | La Jolla | California | 92093 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | New Haven | Connecticut | 06520 | — |
| Not listed | Cedar Rapids | Iowa | 52403 | — |
| Not listed | Annapolis | Maryland | 21401 | — |
| Not listed | Ann Arbor | Michigan | 48109 | — |
| Not listed | Pontiac | Michigan | 48341 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213-3180 | — |
| Not listed | Houston | Texas | 77230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02258464, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2020 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02258464 live on ClinicalTrials.gov.